Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EDIT Editas Medicine	$2.21 -11.2%	$2.48	$0.91 ▼ $4.22	$185.00M	2.19	2.18 million shs	2.26 million shs
LRMR Larimar Therapeutics	$3.58 -2.2%	$3.14	$1.61 ▼ $9.50	$296.35M	0.93	1.57 million shs	1.20 million shs
PRQR ProQR Therapeutics	$2.17 +5.9%	$2.09	$1.07 ▼ $4.62	$228.31M	0.43	217,216 shs	312,555 shs
TELO Telomir Pharmaceuticals	$1.56 -6.6%	$1.72	$1.12 ▼ $8.40	$46.43M	-0.67	9.28 million shs	513,610 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EDIT Editas Medicine	0.00%	-9.43%	-23.26%	+43.51%	-44.33%
LRMR Larimar Therapeutics	0.00%	+4.07%	+5.92%	+72.12%	-53.39%
PRQR ProQR Therapeutics	0.00%	+4.33%	-6.47%	+36.48%	+8.50%
TELO Telomir Pharmaceuticals	0.00%	-11.36%	+34.48%	-37.85%	-63.64%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EDIT Editas Medicine	4.2343 of 5 stars	3.2	3.0	4.3	3.2	2.5	0.6
LRMR Larimar Therapeutics	2.6854 of 5 stars	3.6	2.0	0.0	2.9	3.3	0.0
PRQR ProQR Therapeutics	2.4828 of 5 stars	4.6	3.0	0.0	1.4	0.0	0.0
TELO Telomir Pharmaceuticals	3.1964 of 5 stars	3.8	4.0	0.0	2.2	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EDIT Editas Medicine	2.31	Hold	$4.70	112.67% Upside
LRMR Larimar Therapeutics	3.11	Buy	$18.50	416.76% Upside
PRQR ProQR Therapeutics	3.13	Buy	$8.00	268.66% Upside
TELO Telomir Pharmaceuticals	3.50	Strong Buy	$15.00	861.54% Upside

Current Analyst Ratings Breakdown

Latest TELO, PRQR, EDIT, and LRMR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	PRQR ProQR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
7/11/2025	PRQR ProQR Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/27/2025	PRQR ProQR Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$8.00
6/27/2025	PRQR ProQR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$8.00
6/24/2025	LRMR Larimar Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/24/2025	LRMR Larimar Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$17.00 ➝ $15.00
6/24/2025	LRMR Larimar Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$26.00
5/13/2025	EDIT Editas Medicine	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$8.00 ➝ $4.00
5/13/2025	PRQR ProQR Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$15.00 ➝ $9.00

(Data available from 8/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EDIT Editas Medicine	$32.31M	5.73	N/A	N/A	$1.63 per share	1.36
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	$2.69 per share	N/A
PRQR ProQR Therapeutics	$20.46M	11.16	N/A	N/A	$0.91 per share	2.38
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	$0.02 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EDIT Editas Medicine	-$237.09M	-$3.04	N/A	N/A	N/A	-701.06%	-139.24%	-63.87%	8/13/2025 (Estimated)
LRMR Larimar Therapeutics	-$80.60M	-$1.49	N/A	N/A	N/A	N/A	-52.48%	-46.08%	8/13/2025 (Estimated)
PRQR ProQR Therapeutics	-$30.04M	-$0.46	N/A	N/A	N/A	-238.52%	-61.25%	-28.13%	8/14/2025 (Estimated)
TELO Telomir Pharmaceuticals	-$16.53M	-$0.42	N/A	N/A	N/A	N/A	-2,009.40%	-1,009.72%	8/12/2025 (Estimated)

Latest TELO, PRQR, EDIT, and LRMR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	EDIT Editas Medicine	-$0.40	N/A	N/A	N/A	$1.81 million	N/A
8/13/2025	Q2 2025	LRMR Larimar Therapeutics	-$0.4877	N/A	N/A	N/A	N/A	N/A
8/12/2025	N/A	TELO Telomir Pharmaceuticals	-$0.08	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	PRQR ProQR Therapeutics	-$0.08	-$0.14	-$0.06	-$0.14	$5.01 million	$4.33 million
5/12/2025	Q1 2025	EDIT Editas Medicine	-$0.51	-$0.43	+$0.08	-$0.92	$0.79 million	$4.66 million
5/12/2025	Q1 2025	TELO Telomir Pharmaceuticals	-$0.10	-$0.07	+$0.03	-$0.07	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	N/A
PRQR ProQR Therapeutics	N/A	N/A	N/A	N/A	N/A
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EDIT Editas Medicine	N/A	3.08	3.08
LRMR Larimar Therapeutics	N/A	7.48	7.48
PRQR ProQR Therapeutics	N/A	4.10	4.10
TELO Telomir Pharmaceuticals	N/A	0.75	0.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EDIT Editas Medicine	71.90%
LRMR Larimar Therapeutics	91.92%
PRQR ProQR Therapeutics	32.65%
TELO Telomir Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
EDIT Editas Medicine	1.90%
LRMR Larimar Therapeutics	4.50%
PRQR ProQR Therapeutics	8.40%
TELO Telomir Pharmaceuticals	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EDIT Editas Medicine	230	83.71 million	82.12 million	Optionable
LRMR Larimar Therapeutics	30	82.78 million	79.05 million	Optionable
PRQR ProQR Therapeutics	180	105.21 million	96.38 million	Optionable
TELO Telomir Pharmaceuticals	1	29.76 million	N/A	N/A

TELO, PRQR, EDIT, and LRMR Headlines

Recent News About These Companies

Telomir Pharmaceuticals (TELO) Projected to Post Earnings on Tuesday

5 hours ago | americanbankingnews.com

Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic ...

August 8 at 8:26 AM | kansascity.comK

Telomir Flat on Trial Data Release

August 7, 2025 | baystreet.ca

Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic Dysfunction

August 7, 2025 | accessnewswire.comA

Telomir Pharmaceuticals (TELO) Expected to Announce Earnings on Tuesday

August 6, 2025 | marketbeat.com

Telomir Pharmaceuticals Announces Promising Preclinical Results

July 26, 2025 | theglobeandmail.com

Telomir Pharmaceuticals stock surges on promising Progeria treatment results

July 25, 2025 | investing.com

TELO Announces Another Important Breakthrough

July 25, 2025 | finance.yahoo.com

Telomir Pharmaceuticals Reports Telomir-1's Unique Profile Restores Mitochondrial Health While Improving Oxidative Stress Without Promoting Cell Proliferation in Diseased Human Cell Lines Highlighting Potential Relevance to Neurodegenerative Pathways in Alzheimer's and Parkinson's

July 24, 2025 | accessnewswire.comA

Telomir Pharmaceuticals (NASDAQ:TELO) Trading Down 5% - Here's What Happened

July 23, 2025 | marketbeat.com

Telomir Pharmaceuticals Skyrockets 150% on Breakthrough Preclinical Cancer Results

July 18, 2025 | msn.com

Telomir Pharmaceuticals stock soars after promising cancer treatment data

July 18, 2025 | investing.com

Telomir Pharma Jumps In After-Hours Trading After Drug Reverses Damage In Progeria Cells; Retail Eyes Bigger Gains

July 18, 2025 | msn.com

Telomir Demonstrates Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer Cells, Outperforming Chemotherapy and Rapamycin

July 18, 2025 | accessnewswire.comA

Telomir says data show Telomir-1 reversed epigenetic silencing

July 17, 2025 | msn.com

Telomir Pharmaceuticals Reveals Promising Preclinical Cancer Results

July 17, 2025 | tipranks.com

Telomir Pharmaceuticals Inc News (TELO) - Investing.com

July 1, 2025 | investing.com

Telomir Pharmaceuticals Reports Positive Preclinical Data

June 18, 2025 | tipranks.com

Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria - an Ultra-Rare Genetic Disorder that Causes Rapid Aging

June 18, 2025 | accessnewswire.comA

Telomir Pharma’s Telomir-1 shows dose-dependent restoration of neurological, liver & kidney functions in preclinical for Wilson’s disease

June 14, 2025 | pharmabiz.comP

TELO Rises on Promising Telomir-1 Preclinical Results

June 13, 2025 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why the American Eagle Stock Rally Isn't Just Speculation
By Gabriel Osorio-Mazilli | July 28, 2025
View Why the American Eagle Stock Rally Isn't Just Speculation
3 Short Squeeze Candidates With Big Catalysts on the Horizon
By Dan Schmidt | July 25, 2025
View 3 Short Squeeze Candidates With Big Catalysts on the Horizon
This Drone Stock Is on Sale Despite Big Army Contract
By Jeffrey Neal Johnson | July 31, 2025
View This Drone Stock Is on Sale Despite Big Army Contract
3 Stocks Riding the AI Data Center Buildout Wave
By Chris Markoch | August 6, 2025
View 3 Stocks Riding the AI Data Center Buildout Wave
3 Bullish Biotech Stocks With Explosive Growth Trends
By Chris Markoch | July 21, 2025
View 3 Bullish Biotech Stocks With Explosive Growth Trends

TELO, PRQR, EDIT, and LRMR Company Descriptions

Editas Medicine NASDAQ:EDIT

$2.21 -0.28 (-11.24%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$2.15 -0.06 (-2.49%)

As of 05:47 AM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Larimar Therapeutics NASDAQ:LRMR

$3.58 -0.08 (-2.19%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$3.66 +0.08 (+2.26%)

As of 04:30 AM Eastern

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

ProQR Therapeutics NASDAQ:PRQR

$2.17 +0.12 (+5.85%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$2.13 -0.04 (-1.80%)

As of 08/8/2025 04:28 PM Eastern

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Telomir Pharmaceuticals NASDAQ:TELO

$1.56 -0.11 (-6.59%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$1.65 +0.09 (+5.71%)

As of 05:54 AM Eastern

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time